Administration of a neutralizing antibody against SeP to type 2 diabetes model KKAy mouse improved insulin sensitivity and glucose tolerance, suggesting that SeP is a biomarker of diabetes and a possible therapeutic target10. This evidence concerns the gene SELENOP and type 2 diabetes mellitus.